"目录号: HY-14605A
Neuronal Signaling-
Rasagiline(AGN1135;TVP1012)是MAO-B抑制剂，可作用于原发性帕金森病。
Monoamine Oxidase
相关产品
Tranylcypromine hemisulfate-Clorgiline hydrochloride-R-(-)-Deprenyl hydrochloride-Rasagiline mesylate-Pargyline hydrochloride-Safinamide-Iproniazid phosphate-Mofegiline hydrochloride-Rosmarinic acid-Phenelzine sulfate-Lazabemide-Moclobemide-Ro 41-1049 hydrochloride-Minaprine-Modaline sulfate-
生物活性
Description
Rasagiline(AGN1135;TVP1012) is a new MAO-B inhibitor for the treatment of idiopathic Parkinson's disease. Target: Monoamine Oxidase (MAO)-BRasagiline (N-propargyl-1-(R)-aminoindan) is a novel, highly potent irreversible monoamine oxidase (MAO)-B inhibitor, anti-Parkinsonian drug. Rasagiline is effective as monotherapy or adjunct to L-Dopa for patients with early and late Parkinson's disease (PD) [1]. Rasagiline inhibits MAO-B more potently than selegiline and has the advantage of once-daily dosing. In several large, randomized, placebo-controlled trials, rasagiline has demonstrated efficacy as monotherapy in early PD and as adjunctive therapy in advanced PD. In addition, rasagiline has been shown to have neuroprotective effects in in vitro and in vivo studies. The recently completed delayed-start ADAGIO (Attenuation of Disease Progression with Azilect Given Once-daily) trial suggests a potential disease-modifying effect for rasagiline 1 mg/day, though the clinical import of this finding has yet to be established [2]. Rasagiline has been found to be well tolerated and effective in the treatment of early PD and as adjunctive treatment in motor fluctuations. Whether rasagiline is associated with clinically significant neuroprotection (ie, disease modification) in PD is the subject of ongoing clinical trials [3].
Clinical Trial
NCT01736891
Chongqing Fortune Pharmaceutical Co., Ltd.-Beijing Bionovo Medicine Development Co., Ltd.
Parkinson´s Disease
November 2011
Phase 3
NCT01879748
Teva Pharmaceutical Industries
Parkinson's Disease
June 2013
Phase 1
NCT00203164
Teva Pharmaceutical Industries
Parkinson's Disease
May 2002
Phase 3
NCT01442610
Technische Universität Dresden-Teva Pharmaceutical Industries
Sleep Disturbances-Parkinsons's Disease
October 2011
Phase 4
NCT01652313
H. Lundbeck A/S
Parkinson's Disease
May 2012
Phase 1
NCT01786603
Richard Barohn, MD-University of Kansas Medical Center
Amyotrophic Lateral Sclerosis (ALS)
September 2012
Phase 2
NCT00936676
Teva Pharmaceutical Industries-Teva Neuroscience, Inc.-H. Lundbeck A/S
Parkinson's Disease
July 2009
NCT01168596
University of Florida
Parkinson's Disease
December 2009
Phase 4
NCT01032486
Teva Pharmaceutical Industries
Parkinson's Disease
December 2009
Phase 4
NCT00203177
Teva Pharmaceutical Industries
Parkinson's Disease
October 2001
Phase 3
NCT00755027
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Parkinson's Disease
September 2008
Phase 4
NCT01178047
University of Zurich-H. Lundbeck A/S
Parkinson's Disease
September 2011
Phase 4
NCT01879241
University of Ulm
Amyotrophic Lateral Sclerosis
June 2013
Phase 2
NCT01192503
University of Virginia-Teva Neuroscience, Inc.
Restless Legs Syndrome
September 2010
Phase 2-Phase 3
NCT01723228
Teva Branded Pharmaceutical Products, R&D Inc.-Teva Pharmaceutical Industries
Parkinson's Disease
November 2012
Phase 4
NCT00977665
Teva Pharmaceutical Industries-H. Lundbeck A/S
Multiple System Atrophy
December 2009
Phase 2
NCT01556165
H. Lundbeck A/S
Parkinson's Disease
April 2012
Phase 3
NCT00696215
Istanbul University
Parkinson's Disease
June 2007
Phase 4
NCT01007630
The Parkinson's Institute-Teva Neuroscience, Inc.
Parkinson's Disease
November 2009
Phase 4
NCT01232738
Yunxia Wang, MD-Western ALS Study Group-University of Kansas Medical Center
Amyotrophic Lateral Sclerosis (ALS)
December 2011
Phase 2
NCT00492336
University of Maryland-Stanley Medical Research Institute
Schizophrenia
January 2007
Phase 4
NCT01049984
Teva Neuroscience, Inc.-H. Lundbeck A/S-Teva Pharmaceutical Industries
Parkinson's Disease
December 2009
Phase 4
NCT01532141
Bial - Portela C S.A.
Parkinson Disease
November 2009
Phase 1
NCT01055379
Lundbeck Italia S.p.A.-Teva Pharmaceutical Industries
Depressive Symptoms-Parkinson's Disease
March 2010
Phase 4
NCT02278588
Thomas Guttuso-University at Buffalo
Parkinson's Disease
November 2014
NCT02068625
University Hospital Inselspital, Berne
Retinal Detachment
September 2010
Phase 4
NCT01497652
Georgetown University-Teva Neuroscience, Inc.
Parkinson's Disease
January 2012
Phase 4
NCT00955604
Teva Pharmaceutical Industries
Serotonin Syndrome
July 2009
NCT02359552
The Cleveland Clinic
Alzheimer's Disease
May 2015
Phase 2
NCT01382342
Brown University-Teva Pharmaceuticals USA
Parkinson's Disease
June 2011
Phase 4
NCT01187888
Prof. Dr. Stefan Lorenzl-Teva Pharmaceutical Industries-Ludwig-Maximilians - University of Munich
Progressive Supranuclear Palsy
January 2010
Phase 3
NCT01385735
St. Josef Hospital Bochum
Parkinson Disease
October 2011
Phase 4
NCT00256204
Teva Pharmaceutical Industries
Parkinson's Disease
November 2005
Phase 3
NCT01532128
Bial - Portela C S.A.
Parkinson Disease
November 2009
Phase 1
NCT01048229
Qualissima-H. Lundbeck A/S
Early-stage Parkinson's Disease
October 2008
Phase 4
NCT00203034
Teva Pharmaceutical Industries
Parkinson's Disease
May 2000
Phase 3
NCT00399477
Teva Neuroscience, Inc.-Teva Pharmaceutical Industries
Parkinson's Disease
October 2006
Phase 4
NCT00203138
Teva Pharmaceutical Industries
Parkinson's Disease
June 2004
Phase 3
NCT00104273
Teva Pharmaceutical Industries-Eisai Inc.
Dementia-Alzheimer's Disease
August 2004
Phase 2
NCT00203060
Teva Neuroscience, Inc.-Teva Pharmaceutical Industries
Parkinson's Disease
July 1997
Phase 3
NCT02789020
University of Florida-National Institute of Neurological Disorders and Stroke (NINDS)
Parkinson's Disease
December 2016
NCT01968460
Pharma Two B Ltd.
Parkinson's Disease
December 2013
Phase 2-Phase 3
NCT01215227
Merck Sharp & Dohme Corp.
Parkinson Disease-Idiopathic Parkinson Disease
November 2010
Phase 3
NCT00203125
Teva Pharmaceutical Industries
Parkinson's Disease
October 2000
Phase 3
NCT01155479
Merck Sharp & Dohme Corp.
Parkinson Disease
July 2010
Phase 3
NCT01155466
Merck Sharp & Dohme Corp.
Parkinson Disease
July 14, 2010
Phase 3
View MoreCollapse
References
[1].Leegwater-Kim, J. and E. Bortan, The role of rasagiline in the treatment of Parkinson's disease. Clin Interv Aging, 2010. 5: p. 149-56.
[2].Weinreb, O., et al., Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity. Prog Neurobiol, 2010. 92(3): p. 330-44.
[3].Chen, J.J., D.M. Swope, and K. Dashtipour, Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the